Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials

Published:2023-12 Issue: Volume:149 Page:155710
ISSN:0026-0495
Container-title:Metabolism
language:en
Short-container-title:Metabolism

Author:

Karakasis Paschalis,Patoulias Dimitrios,Pamporis Konstantinos,Stachteas Panagiotis,Bougioukas Konstantinos I.,Klisic Aleksandra,Fragakis Nikolaos,Rizzo Manfredi

Publisher

Elsevier BV

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Reference53 articles.

1. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045;Sun;Diabetes Res Clin Pract,2022

2. 15. Management of diabetes in pregnancy: standards of care in diabetes-2023;ElSayed;Diabetes Care,2023

3. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD);Davies;Diabetologia,2022

4. Efficacy and tolerability of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis;Hussein;Diabetes Obes Metab,2020

5. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes;Sikirica;Diabetes Metab Syndr Obes,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gastrointestinal effects of GLP-1 receptor agonists: mechanisms, management, and future directions;The Lancet Gastroenterology & Hepatology;2024-10

2. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

3. GLP-1R mediates idebenone-reduced blood glucose in mice;Biomedicine & Pharmacotherapy;2024-09

4. Glucagon‐like peptide‐1 receptor agonists in adolescents with overweight or obesity with or without type 2 diabetes multimorbidity—a systematic review and network meta‐analysis;Diabetes, Obesity and Metabolism;2024-07-23

5. A novel approach to exploit Small-Molecule glucagon-like Peptide-1 receptor agonists with high potency;Bioorganic & Medicinal Chemistry;2024-06